[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579750":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":11,"centralContacts":44,"locations":50,"responsibleParty":92,"collaborators":11,"id":94,"slug":95,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":11,"eligibilityCriteria":100,"healthyVolunteers":96,"sex":101,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":11,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":11,"overallStatus":53,"whyStopped":11,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Jiangsu HengRui Medicine Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SHR-A1811 group","EXPERIMENTAL",null,[13],"Drug: SHR-A1811",{"label":15,"type":16,"description":11,"interventionNames":17},"Chemotherapy group","ACTIVE_COMPARATOR",[18,19,20,21],"Drug: Paclitaxel Injection","Drug: Doxorubicin Hydrochloride Liposome Injection","Drug: Gemcitabine Hydrochloride for Injection","Drug: Topotecan Hydrochloride for Injection",[23,28,32,36,40],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"DRUG","SHR-A1811","SHR-A1811.",[9],{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"Paclitaxel Injection","Paclitaxel Injection.",[15],{"type":24,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"Doxorubicin Hydrochloride Liposome Injection","Doxorubicin Hydrochloride Liposome Injection.",[15],{"type":24,"name":37,"description":38,"armGroupLabels":39,"otherNames":11},"Gemcitabine Hydrochloride for Injection","Gemcitabine Hydrochloride for Injection.",[15],{"type":24,"name":41,"description":42,"armGroupLabels":43,"otherNames":11},"Topotecan Hydrochloride for Injection","Topotecan Hydrochloride for Injection.",[15],[45],{"name":46,"role":47,"phone":48,"phoneExt":11,"email":49},"Yuanchao Wang","CONTACT","0518-82342973","yuanchao.wang@hengrui.com",[51,74],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology","RECRUITING","Wuhan","Hubei","430030","China","CN",{"type":60,"coordinates":61},"Point",[62,63],114.26667,30.58333,{"lat":63,"lon":62},[66,70,72],{"name":67,"role":47,"phone":68,"phoneExt":11,"email":69},"Ding Ma","027-83663821","ding_ma2022@163.com",{"name":67,"role":71,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"name":73,"role":71,"phone":11,"phoneExt":11,"email":11},"Qinglei Gao",{"facility":75,"status":53,"city":76,"state":77,"zip":78,"country":57,"countryCode":58,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Qilu Hospital of Shandong University","Jinan","Shandong","250012",{"type":60,"coordinates":80},[81,82],116.99722,36.66833,{"lat":82,"lon":81},[85,89,90],{"name":86,"role":47,"phone":87,"phoneExt":11,"email":88},"Beihua Kong","18653199168","kongbeihua@sdu.edu.cn",{"name":86,"role":71,"phone":11,"phoneExt":11,"email":11},{"name":91,"role":71,"phone":11,"phoneExt":11,"email":11},"Kun Song",{"type":93,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100579750","phase-3-a-study-of-shr-a1811-in-subjects-with-ovarian-cancer-100579750",false,"NCT06828354","A Study of SHR-A1811 in Subjects With Ovarian Cancer","An Open-label, Randomized, Multicenter Phase III Clinical Trial of SHR-A1811 Versus Investigator-selected Chemotherapy for Platinum-resistant Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","Inclusion Criteria:\n\n1. The subjects voluntarily joined the study and signed the Informed consent forms (ICF).\n2. Measurable disease, as defined by RECIST v1.1.\n3. The Eastern Cancer Cooperative Group (ECOG) performance status of 0 or 1.\n4. Life expectancy ≥ 12 weeks.\n\nExclusion Criteria:\n\n1. Symptomatic, untreated or active central nervous system metastases.\n2. Have uncontrolled or severe cardiovascular disease.\n3. With any active autoimmune disease or history of autoimmune disease.\n4. Patients with active hepatitis B or hepatitis C.\n5. Severe infections prior to initiation of study treatment.\n6. Patients with active tuberculosis.","FEMALE","18 Years","75 Years",{"count":105,"type":106},300,"ESTIMATED","INTERVENTIONAL",[109],"PHASE3","This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.",[112],"Ovarian Cancer","2026-04-15",{"date":115,"type":116},"2026-04-20","ACTUAL",{"date":118,"type":116},"2025-03-13",{"date":120,"type":106},"2027-12",{"name":5,"class":6},2]